Human Growth Hormone (HGH) dosing & administration
The master hormone that acts as your body's repair crew—building lean muscle, burning stubborn fat, strengthening bones, and helping you recover like you did in your younger years [2][3].
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Dosing
How much do I take?
Subcutaneous: A small injection into the fatty layer just under the skin — the same way insulin is given.
Bioavailability High — most of the dose reaches your bloodstream, just more gradually than an IV.
Titration schedule
0.15-0.30 mg/day (approx. 0.2 mg/day)
Frequency
Once daily
Duration
First 1-2 months before titration
Titrate by 0.1-0.2 mg/day to target (commonly 0.2-0.6 mg/day)
Frequency
Once daily
Duration
Adjusted every 1-2 months
Dose titrated every 1-2 months to clinical response and serum IGF-1 per FDA label [6].
Not more than 0.04 mg/kg/week initially, up to 0.08 mg/kg/week
Frequency
Divided into 6-7 daily injections
Duration
Titrated at 4-8 week intervals
FDA-labeled weight-based regimen ceiling for adult GH deficiency (Genotropin) [6].
Timing
Best time to take
Most people inject first thing in the morning on an empty stomach, or before bed. Morning dosing mimics your body's natural GH pulse and avoids potential sleep disruption. Evening/bedtime dosing can enhance the natural nighttime GH surge during deep sleep [8][9].
With food?
Best taken on an empty stomach. Insulin and blood sugar spikes from food can blunt HGH's effects. Wait at least 30-60 minutes after injection before eating, especially carbohydrates. Some users inject 2-3 hours after their last meal.
If stacking
If combining with peptides like CJC-1295 or Ipamorelin, you can inject at the same time but use different sites. Space HGH away from meals by at least 30 minutes. If using insulin (only under medical supervision), timing becomes critical—consult a physician [16].
Adjusting your dose
Increase if
- You've been on your current dose for 4-6 weeks with no side effects
- You're not seeing the expected improvements in recovery, sleep, or body composition
- Your IGF-1 levels are still below optimal range on bloodwork
- Your doctor recommends an increase based on your response
Decrease if
- You experience significant water retention or swelling that doesn't resolve
- Joint pain or carpal tunnel symptoms become bothersome
- You develop headaches or vision changes
- Blood sugar levels become elevated on testing
Signs of right dose
- Better sleep quality—falling asleep easier and waking refreshed
- Improved recovery from workouts with less soreness
- Gradual improvements in body composition (leaner, more muscular)
- Manageable or no side effects at your current dose
Administration
How do I use it?
Reconstitution
What you need
Injection
Route
Subcutaneous injection (into the fat layer just under the skin)—the most common and easiest method for self-administration
Best sites
Storage
Before reconstitution
Keep unopened HGH vials refrigerated at 36-46°F (2-8°C). Protect from light and keep in original packaging. Never freeze powder form. Most pharmaceutical HGH has an 18-24 month shelf life when properly stored. Check expiration dates.
After reconstitution
Refrigerate immediately after mixing at 36-46°F (2-8°C). Never freeze reconstituted HGH—freezing denatures the protein and destroys the hormone. Avoid shaking—swirl gently if needed. Use within 28 days. Keep away from light.
Signs of degradation — discard the vial
Sample daily schedule
Morning (immediately upon waking, 6-7 AM)
Full daily dose (e.g., 2 IU) injection
Site: Rotate between belly, thigh, and arm
This is the most popular timing. Inject on an empty stomach and wait 30-60 minutes before eating breakfast. This mimics your body's natural morning GH pulse and gives you energy for the day.
Split dosing: Morning + Bedtime
Half in AM (e.g., 1 IU), half before bed (e.g., 1 IU) injection
Site: Different sites for each injection
Some users prefer splitting their dose to maintain steadier blood levels. The nighttime dose can enhance the natural GH surge during deep sleep. This protocol may help reduce side effects from a single larger dose.
Safety
Is it safe?
Side effects
Commonly reported: Water retention and swelling, Joint and muscle pain, Carpal tunnel symptoms, Headaches
Less common: Elevated blood sugar, Gynecomastia (in men)
Stop and seek help if
- Severe or persistent headaches with vision changes—may indicate intracranial pressure
- Significant swelling that doesn't improve with dose reduction
- Blood sugar levels becoming diabetic range despite management
- Development of new growths, lumps, or concerning symptoms
- Severe joint pain or carpal tunnel that interferes with daily life
- Any allergic reaction—hives, difficulty breathing, facial swelling
Human Growth Hormone is a prescription medication in most countries. This information is for educational purposes only and does not constitute medical advice. Always work with a qualified healthcare provider before starting, stopping, or adjusting HGH therapy. Regular monitoring through blood tests is essential for safe use.
Flagged pairings
- IGF-1 LR3 — Both increase IGF-1 activity. Combining may lead to excessive IGF-1 levels. Use with caution and monitor IGF-1 levels closely.
- Insulin — Complex interaction requiring expert management. HGH increases insulin resistance while insulin lowers blood sugar. Only combine under direct medical supervision with careful monitoring.
Published research
What the studies show
Fernández-Garza LE, Guillen-Silva F, Sotelo-Ibarra MA, et al. · 2025
This comprehensive review found that growth hormone plays a key role in body composition, muscle mass, bone formation, and metabolism. While showing promising anti-aging effects, the review emphasizes that long-term safety and efficacy for healthy aging still require more research.
Sun F, Yang A, Jin Y, et al. · 2025
This meta-analysis of 10 randomized trials found that low-dose HGH therapy significantly reduces visceral (belly) fat and increases thigh muscle mass in obese individuals. No serious adverse events were reported, suggesting low-dose HGH may help with sarcopenic obesity.
Xu Q, Yang Y, Ke J, et al. · 2025
This study showed that continued HGH therapy significantly improved bone mineral density and grip strength in patients with GH deficiency. Patients who stopped treatment experienced bone density decline and worsening lipid profiles, highlighting the importance of appropriate treatment duration.
Woelfle J, Kreitschmann-Andermahr I, Strasburger CJ, et al. · 2025
This real-world registry study documented the first 100 patients on newer long-acting GH formulations, providing insights into dosing patterns and patient selection outside clinical trials. The study highlights evolving treatment approaches in GH therapy.
Cianfarani S · 2025
This review explored how individual responses to GH therapy vary significantly despite standardized protocols, emphasizing the need for personalized approaches. The study highlights that treatment success depends on diagnosis, patient factors, and proper dose optimization.
Pfizer (FDA label) · 2020
FDA-labeled adult growth hormone deficiency dosing: non-weight-based start ~0.2 mg/day (0.15-0.30 mg/day) titrated every 1-2 months by 0.1-0.2 mg/day; weight-based start not more than 0.04 mg/kg/week up to 0.08 mg/kg/week, given as daily subcutaneous injections.
Rudman D, Feller AG, Nagraj HS, et al. · 1990
Six-month controlled trial in 21 healthy men aged 61-81 with low IGF-1 levels. Growth hormone treatment increased lean body mass by 8.8%, decreased adipose tissue mass by 14.4%, and increased skin thickness by 7.1%, suggesting diminished GH secretion contributes to the loss of lean mass and skin thinning seen in old age.
Iranmanesh A, Lizarralde G, Veldhuis JD · 1991
24-hour blood sampling study in 21 healthy men aged 21-71. Each decade of increasing age reduced the daily GH production rate by about 14%, with age and body mass index together accounting for more than 60% of the variability in 24-hour GH production.
Van Cauter E, Plat L · 1996
Review of GH secretion during sleep. In adults, the most reproducible GH pulse occurs shortly after sleep onset in association with the first phase of slow-wave (deep) sleep; in men roughly 70% of sleep GH pulses coincide with slow-wave sleep, and sleep-related secretion depends primarily on growth hormone-releasing hormone.
Doessing S, Heinemeier KM, Holm L, et al. · 2010
Fourteen days of growth hormone administration in healthy young adults increased collagen synthesis in tendon and skeletal muscle (tendon collagen I mRNA rose 3.9-fold) without affecting myofibrillar protein synthesis, indicating GH primarily strengthens connective/matrix tissue rather than directly driving muscle-cell growth.
Herndon DN, Barrow RE, Kunkel KR, et al. · 1990
Randomized double-blind trial in 40 severely burned children. Recombinant growth hormone at 0.2 mg/kg/day significantly shortened skin-graft donor-site healing time and reduced hospital stay from 0.80 to 0.54 days per percent of body surface burned.
Liu H, Bravata DM, Olkin I, et al. · 2007
Systematic review of randomized trials of GH in healthy elderly people (31 articles, 18 study populations). GH produced small body-composition changes (about 2.1 kg less fat and 2.1 kg more lean mass) but treated participants were significantly more likely to experience soft tissue edema, arthralgias, carpal tunnel syndrome, and gynecomastia. The review also notes that distribution of GH as an anti-aging agent is illegal in the United States.
Moller N, Jorgensen JO · 2009
Comprehensive review of GH metabolic actions in humans. The most prominent metabolic effect of GH is a marked increase in lipolysis and free fatty acid levels; GH also increases protein synthesis and antagonizes insulin's effects on glucose metabolism, which explains its ability to induce insulin resistance.
Ayyar VS · 2011
Historical review of growth hormone therapy. After cadaver-derived GH was discontinued in April 1985 because of Creutzfeldt-Jakob disease cases, the FDA rapidly approved Genentech's recombinant (synthetic) growth hormone, which was introduced in the United States in 1985.
Baumann GP · 2012
Review of GH doping in sports. GH use in athletic competition is banned by the World Anti-Doping Agency; the blood-based isoform test distinguishes recombinant GH from endogenous GH within roughly 12-24 hours of the last dose, and a biomarker test extends the detection window to 1-2 weeks.
Sigalos JT, Pastuszak AW · 2018
Review of growth hormone secretagogues, including GH-releasing peptides. These agents promote pulsatile release of the body's own GH, which remains subject to negative feedback and can prevent supra-therapeutic GH levels; available studies indicate they are well tolerated, with some concern for increased blood glucose from decreased insulin sensitivity.
Boguszewski CL, Boguszewski MCDS · 2019
Endocrine Reviews analysis of the relationship between the GH axis and cancer. Replacement GH therapy in GH-deficient adults and short children has been shown to be safe when no other risk factors for malignancy are present, while caution is advised in cancer survivors and certain genetic syndromes.
Gotherstrom G, Elbornsson M, Stibrant-Sunnerhagen K, et al. · 2009
Prospective 10-year study of continuous GH replacement in 109 GH-deficient adults. Treatment produced a sustained increase in lean mass and, after correction for age and gender, sustained and partly progressive increases in muscle strength, with approximately normalized muscle strength after 10 years of uninterrupted use.
Head to head
Human Growth Hormone (HGH) compared
Want the full picture?
The complete Human Growth Hormone (HGH) research profile: mechanism of action, clinical studies, effectiveness timeline, and FAQ.